课题基金 / 基金详情

Establishment of Antisense Therapy for Hematological Mailg-nancies Targeted Their Rearranged Genes.

Establishment of Antisense Therapy for Hematological Mailg-nancies Targeted Their Rearranged Genes.
针对血液肿瘤重排基因的反义疗法的建立。
批准号:
09671094
负责人:
MAEKAWA Taira
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998

项目摘要

项目成果

MAEKAWA Taira的其他基金

相似基金

相关文献

中文摘要
翻译
在本研究项目中,我们阐明了反义寡脱氧核苷酸(AS ODN)对重排和过表达癌基因抑制人白血病细胞增殖的机制。1) BCR-ABL AS ODN可通过诱导慢性髓系白血病(CML)细胞凋亡,有效抑制CML细胞的增殖。c-myc AS ODN能抑制人白血病细胞hl60的增殖,使G_1/S交界区白血病细胞数量突变上调。c-myc AS ODN还通过Fas/Fas配体系统抑制类风湿关节炎滑膜细胞的增殖并诱导细胞凋亡。2)建立了具有硫代磷和二酯键嵌合骨架结构的AS ODN的合成和纯化方法。5′端和3′端的前三个键都是通过硫代化学合成的。我们已经证明这些嵌合类似物能够抵抗核酸酶的降解。3)上述嵌合类似物具有更少的非特异性效应或适体效应,而当使用具有全硫代键的AS odn时,通常会遇到这种效应。4)我们已经发现,具有嵌合骨架的AS odn可以有效地对抗Bcl-2、c-myc、促红细胞生成素受体和基质衍生因子1,并且我们发现了新的靶向反义序列来降低Bcl-2的表达。
英文摘要
In this research project, we have clarified followings concerning the mechanism of suppression of the proliferation of human leukemic cells by antisense oligodeoxynucleotides (AS ODN) for rearranged and over-expressed oncogenes.1) BCR-ABL AS ODN could effectively suppress the proliferation of chronic myeloid leukemia (CML) cells by the induction of apoptosis of these leukemia cells. c-myc AS ODN could inhibit the proliferation of human leukemia cells HL6O, and the abrupt up-regulation of number of leukemia cells in G_1/S boundary. c-myc AS ODN also inhibited the proliferation of synovial cells from patients with rheumatoid arthritits and induced the apoptosis through Fas/Fas ligand system.2) We have established the synthesis and purification methods of AS ODN with chimeric backbone structure of phosphorothioate and phosphodiester linkages. The first three linkages of both 5'- and 3'-end are synthesized by phosphorothioate chemistry. We have shown these chimeric analogues were resistant to the degradation by nuclease.3) The above chimeric analogue have much less non-specific effects or aptamer effects that are often encountered when AS ODNs with all-phosphorothioate linkages are used.4) We have shown that AS ODNs with chimeric backbones against Bcl-2, c-myc, erythropoietin receptor, and stromal-derived factor 1 effectively work as functional antisense molecules, and we have found the novel target antisense sequence to reduce the Bcl-2 expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
前川 平: "がんの遺伝子治療をアンチセンス治療" 治療. 81. 865-870 (1999)
Taira Maekawa:“癌症的反义基因疗法”治疗。81. 865-870 (1999)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
前川 平: "遺伝子異常をターゲットとしたアンチセンス法" 血液・免疫・腫瘍. 2. 124-130 (1997)
Taira Maekawa:“针对遗传异常的反义方法”血液学/免疫学/肿瘤。2. 124-130 (1997)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kishi,K.et al: "Hematopoielic cytokine-dependent differentiation to easinophils and neutropbils in a newly establisbed..." Exp.Hematol. 26. 135-142 (1998)
Kishi,K.等人:“在新建立的床中,造血细胞因子依赖性分化为嗜酸性粒细胞和中性粒细胞……”Exp.Hematol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 23 条
    Eradication of chronic myelogenous leukemia stem cells and abnormal clone with T315I point mutation
    • 批准号:
      21390293
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.07万
    • 财政年份:
      2009
    • 负责人:
      MAEKAWA Taira
    • 依托单位:
    Molecular therapeutics for imatinib-resistant Ph-positive leukemias with newly developed Bcr-Abl/Lyn tyrosine kinase inhibitor
    • 批准号:
      18390283
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.86万
    • 财政年份:
      2006
    • 负责人:
      MAEKAWA Taira
    • 依托单位:
    Possible mechanism of hematopietic stem cells homing to the bone marrow microenvironment
    Development of Antisense Therapy for Hematological Mailgnancies Targeted Their Rearranged Genes.
    • 批准号:
      11670983
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      1999
    • 负责人:
      MAEKAWA Taira
    • 依托单位:
    海外基金